Muslimov, A. et al. The dual role of the innate immune system in the effectiveness of mRNA therapeutics. Int. J. Mol. Sci. 24, 14820 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonelli, M. et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. Ann. Rheum. Dis. 81, 687–694 (2022).

Article  CAS  PubMed  Google Scholar 

Mrak, D. et al. Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. Nat. Commun. 13, 5362 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brenner, S., Jacob, F. & Meselson, M. An unstable intermediate carrying information from genes to ribosomes for protein synthesis. Nature 190, 576–581 (1961).

Article  CAS  PubMed  Google Scholar 

Wolff, J. A. et al. Direct gene transfer into mouse muscle in vivo. Science 247, 1465–1468 (1990).

Article  CAS  PubMed  Google Scholar 

Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duke University. A safety and feasibility study of active immunotherapy in patients with metastatic prostate carcinoma using autologous dendritic cells pulsed with RNA encoding prostate specific antigen, PSA. https://clinicaltrials.gov/study/NCT00004211 (2013).

Heiser, A. et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Investig. 109, 409–417 (2002).

Article  CAS  PubMed  PubMed Central  Google Scholar 

University Hospital Tuebingen. Induction of specific immune responses against melanoma-associated antigens in vivo by intradermal vaccination with stabilized tumor mRNA—a clinical Phase I/II trial. https://clinicaltrials.gov/study/NCT00204607 (2007).

Weide, B. et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J. Immunother. 32, 498–507 (2009).

Article  CAS  PubMed  Google Scholar 

Karikó, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165–175 (2005).

Article  PubMed  Google Scholar 

Dolgin, E. The tangled history of mRNA vaccines. Nature 597, 318–324 (2021).

Article  CAS  PubMed  Google Scholar 

Alberer, M. et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390, 1511–1520 (2017).

Article  CAS  PubMed  Google Scholar 

Lu, C. et al. Safety, Immunogenicity, and mechanism of a rotavirus mRNA-LNP vaccine in mice. Viruses 16, 211 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang, L., Tang, L., Zhang, M. & Liu, C. Recent advances in the molecular design and delivery technology of mRNA for vaccination against infectious diseases. Front. Immunol. 13, 896958 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han, G. et al. Advances in mRNA therapeutics for cancer immunotherapy: from modification to delivery. Adv. Drug Deliv. Rev. 199, 114973 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boreikaitė, V. & Passmore, L. A. 3′-end processing of eukaryotic mRNA: machinery, regulation, and impact on gene expression. Annu. Rev. Biochem. 92, 199–225 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Shen, G., Liu, J., Yang, H., Xie, N. & Yang, Y. mRNA therapies: pioneering a new era in rare genetic disease treatment. J. Control Release 369, 696–721 (2024).

Article  CAS  PubMed  Google Scholar 

Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817–838 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kwon, S., Kwon, M., Im, S., Lee, K. & Lee, H. mRNA vaccines: the most recent clinical applications of synthetic mRNA. Arch. Pharm. Res. 45, 245–262 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bourke, A. M., Schwarz, A. & Schuman, E. M. De-centralizing the central dogma: mRNA translation in space and time. Mol. Cell 83, 452–468 (2023).

Article  CAS  PubMed  Google Scholar 

Bai, C., Wang, C. & Lu, Y. Novel vectors and administrations for mRNA delivery. Small 19, 2303713 (2023).

Article  CAS  Google Scholar 

Su, L.-J. et al. Delivery of mRNA for cancer therapy: progress and prospects. Nano Today 53, 102013 (2023).

Article  CAS  Google Scholar 

Ye, Z. et al. The mRNA vaccine revolution: COVID-19 has launched the future of vaccinology. ACS Nano 17, 15231–15253 (2023).

Article  CAS  PubMed  Google Scholar 

Pan, S., Fan, R., Han, B., Tong, A. & Guo, G. The potential of mRNA vaccines in cancer nanomedicine and immunotherapy. Trends Immunol. 45, 20–31 (2024).

Article  CAS  PubMed  Google Scholar 

Metkar, M., Pepin, C. S. & Moore, M. J. Tailor made: the art of therapeutic mRNA design. Nat. Rev. Drug Discov. 23, 67–83 (2024).

Article  CAS  PubMed  Google Scholar 

Kawamoto, Y., Wu, Y., Takahashi, Y. & Takakura, Y. Development of nucleic acid medicines based on chemical technology. Adv. Drug Deliv. Rev. 199, 114872 (2023).

Article  CAS  PubMed  Google Scholar 

Cao, Q., Fang, H. & Tian, H. mRNA vaccines contribute to innate and adaptive immunity to enhance immune response in vivo. Biomaterials 310, 122628 (2024).

Article  CAS  PubMed  Google Scholar 

Sun, H., Li, K., Liu, C. & Yi, C. Regulation and functions of non-m6A mRNA modifications. Nat. Rev. Mol. Cell Biol. 24, 714–731 (2023).

Article  CAS  PubMed  Google Scholar 

Rodell, R., Robalin, N. & Martinez, N. M. Why U matters: detection and functions of pseudouridine modifications in mRNAs. Trends Biochem. Sci. 49, 12–27 (2024).

Article  CAS  PubMed  Google Scholar 

Lin, S. & Kuang, M. RNA modification-mediated mRNA translation regulation in liver cancer: mechanisms and clinical perspectives. Nat. Rev. Gastroenterol. Hepatol. 21, 267–281 (2024).

Article  CAS  PubMed  Google Scholar 

Flamand, M. N., Tegowski, M. & Meyer, K. D. The proteins of mRNA modification: writers, readers, and erasers. Annu. Rev. Biochem. 92, 145–173 (2023).

Article  CAS  PubMed  PubMed Central